Finerenone — Membership Pricing

Other medications in Diabetes & Metabolism

• Glimepiride
• Glipizide
• Glyburide
• Insulin Aspart
• Insulin Degludec
• Insulin Detemir
• Insulin Glargine
• Insulin Lispro

About Finerenone

Finerenone, known by its brand name Kerendia, is a vital medication for individuals managing chronic kidney disease associated with type 2 diabetes. It works to slow disease progression and protect vital organs. At TheDrugClub, we understand the financial burden of such critical prescriptions. Our mission is to help members access finerenone and other medications at more affordable prices, ensuring better health outcomes without compromise.

What Finerenone Treats

Finerenone, marketed under the brand name Kerendia, is an oral medication approved for adults with chronic kidney disease (CKD) associated with type 2 diabetes. This condition significantly increases the risk of kidney failure and cardiovascular complications. Finerenone is prescribed to reduce the risk of sustained decline in kidney function, kidney

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Finerenone is approved for (FDA label)

Kerendia is indicated to reduce the risk of: sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40%. Kerendia is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated to reduce the risk of: sustained estimated glomerular filtration rate (eGFR) decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2DM). ( 1 ) cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adult patients with heart failure with left ventricular ejection fraction (LVEF) ≥ 40% ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 28, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Finerenone (FDA label)

Kerendia is available as film-coated, oblong tablets in three strengths. 10 mg: pink, with "FI" on one side, "10" on the other side. 20 mg: yellow, with "FI" on one side, "20" on the other side. 40 mg: gray-orange, with "FI" on one side, "40" on the other side. Tablets: 10 mg, 20 mg, and 40 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: fc726765-5d5a-4d6e-b037-b847bda9fb7c. SPL document ID: 28aa9af2-2939-46e0-8c9c-af939e81b551. Label effective date: August 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Finerenone (FDA label)

The following serious adverse reactions are discussed elsewhere in the labeling: Hyperkalemia [see Warnings and Precautions (5.1) ] Adverse reactions occurring in ≥ 1% of patients on Kerendia and more frequently than placebo are hyperkalemia, hypotension, and hyponatremia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare Pharmaceuticals Inc. at 1-888-842-2937 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: fc726765-5d5a-4d6e-b037-b847bda9fb7c. SPL document ID: 28aa9af2-2939-46e0-8c9c-af939e81b551. Label effective date: August 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Finerenone (FDA label)

Kerendia is contraindicated in patients: Who are hypersensitive to any component of this product [see Adverse Reactions (6.2) ] . Who are receiving concomitant treatment with strong CYP3A4 inhibitors [see Drug Interactions (7.1) ]. With adrenal insufficiency. Concomitant use with strong CYP3A4 inhibitors. ( 4 , 7.1 ) Patients with adrenal insufficiency. ( 4 ) Hypersensitivity to any component of this product. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: fc726765-5d5a-4d6e-b037-b847bda9fb7c. SPL document ID: 28aa9af2-2939-46e0-8c9c-af939e81b551. Label effective date: August 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Finerenone (FDA label)

Hyperkalemia. Patients with decreased kidney function and higher baseline potassium levels are at increased risk. Monitor serum potassium levels and adjust dose as needed. ( 2.1 , 2.2 , 2.3 , 5.1 ) Worsening of Renal Function in Patients with Heart Failure. Measure eGFR and adjust dose as needed. ( 2.1 , 2.3 , 6.1 ) 5.1 Hyperkalemia Kerendia can cause hyperkalemia [see Adverse Reactions (6.1) ] . The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia.

Source: FDA prescribing information (DailyMed). Set ID: fc726765-5d5a-4d6e-b037-b847bda9fb7c. SPL document ID: 28aa9af2-2939-46e0-8c9c-af939e81b551. Label effective date: August 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Finerenone (FDA label)

Strong CYP3A4 Inhibitors: Use is contraindicated. ( 7.1 ) Grapefruit or grapefruit juice: Avoid concomitant use. ( 7.1 ) Moderate or weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either Kerendia or the moderate or weak CYP3A4 inhibitor, and adjust Kerendia dosage as appropriate ( 7.1 ) Strong or moderate CYP3A4 Inducers: Avoid concomitant use. ( 7.1 ) Sensitive CYP2C8 substrates at Kerendia 40 mg: Monitor more frequently for adverse reactions. ( 7.2 ) 7.1 Effect of Other Drugs on Kerendia Strong CYP3A4 Inhibitors Kerendia is a CYP3A4 substrate. Concomitant use with a strong CYP3A4 inhibitor increases finerenone exposure [see Clinical Pharmacology (12.3) ] , which may increase the risk of Kerendia adverse reactions. Concomitant use of Kerendia with strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) ] . Avoid concomitant intake of grapefruit or grapefruit juice.

Source: FDA prescribing information (DailyMed). Set ID: fc726765-5d5a-4d6e-b037-b847bda9fb7c. SPL document ID: 28aa9af2-2939-46e0-8c9c-af939e81b551. Label effective date: August 28, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.